Iterum Therapeutics plc
ITRM
$1.03
-$0.05-4.63%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.80% | -4.08% | -12.79% | -30.80% | -41.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.61% | -39.82% | 11.49% | 43.00% | 56.23% |
| Operating Income | 60.61% | 39.82% | -11.49% | -43.00% | -56.23% |
| Income Before Tax | 35.02% | 1.08% | 50.51% | 31.05% | 14.44% |
| Income Tax Expenses | -60.85% | -37.59% | 340.25% | 18,033.33% | 103.65% |
| Earnings from Continuing Operations | 35.44% | 1.75% | 49.70% | 29.99% | 13.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.44% | 1.75% | 49.70% | 29.99% | 13.64% |
| EBIT | 60.61% | 39.82% | -11.49% | -43.00% | -56.23% |
| EBITDA | 59.73% | 38.42% | -14.79% | -47.10% | -59.95% |
| EPS Basic | 55.67% | 17.77% | 55.81% | 35.96% | 18.47% |
| Normalized Basic EPS | 55.38% | 17.17% | 56.56% | 36.95% | 19.21% |
| EPS Diluted | 55.61% | 17.77% | 55.81% | 35.96% | 18.47% |
| Normalized Diluted EPS | 55.38% | 17.17% | 56.56% | 36.95% | 19.21% |
| Average Basic Shares Outstanding | 51.83% | 27.96% | 16.05% | 10.44% | 5.92% |
| Average Diluted Shares Outstanding | 51.83% | 27.96% | 16.05% | 10.44% | 5.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |